Status:

COMPLETED

A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union

Lead Sponsor:

Universidad Autonoma de Madrid

Conditions:

Non Union Fracture

Eligibility:

All Genders

18-99 years

Phase:

PHASE3

Brief Summary

ORTHOUNION is a multi-centre, open, comparative, randomized, clinical trial with three parallel arms that aims to compare the efficacy of three treatments to enhance bone healing in patients with long...

Detailed Description

Bone injuries represent an important world medical problem producing significant healthcare and societal expenditure. While most bone injuries are not severe and are capable of healing through bone re...

Eligibility Criteria

Inclusion

  • Age 18 years and older, both sexes
  • Traumatic isolated closed or open Gustilo I and II, IIIA and IIIB humerus, tibial or femur diaphyseal or metaphysodiaphyseal fracture with a status of atrophic, oligotrophic or normotrophic non-union.
  • Able to understand, accept and sign informed consent
  • Medical health coverage
  • Able to understand and accept the study constraints

Exclusion

  • Hypertrophic non-unions
  • Segmental bone loss requiring specific therapy (bone transport, vascularized graft, large structural allograft, megaprosthesis, etc)
  • Unrecovered vascular or neural injury
  • Other fractures causing interference with weight bearing
  • Visceral injuries or diseases interfering with callus formation (severe cranioencephalic trauma, etc.)
  • Active infection of any location and aetiology
  • Surgical contraindication of any cause
  • Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control.
  • Malignant tumour (past history or concurrent disease)(except carcinoma in situ or basalioma in remission)
  • History of bone harvesting on iliac crest contraindicating new iliac crest bone graft harvesting or bone marrow collection
  • Insulin dependent diabetes
  • Any evidence (confirmed by PCR) of active infection with HIV, Hepatitis B or Hepatitis C infection
  • Any evidence of Syphilis
  • Known allergies to products involved in the production process of MSC
  • Corticoid or immunosuppressive therapy more than one week in the three months prior to study inclusion
  • Autoimmune inflammatory disease
  • Current treatment by biphosphonates not stopped three months prior to study inclusion
  • Impossibility to meet at the appointments for the follow up
  • Participation in another therapeutic trial in the previous 3 months
  • Second non-union in case of bilateral or multiple non-unions (only one non-union per patient will be included in the trial)

Key Trial Info

Start Date :

September 5 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 15 2023

Estimated Enrollment :

46 Patients enrolled

Trial Details

Trial ID

NCT03325504

Start Date

September 5 2017

End Date

December 15 2023

Last Update

December 4 2024

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

CHU Clermont-Ferrand

Clermont-Ferrand, France

2

Department of Orthopaedic Surgery, Hospital Henri Mondor

Créteil, France

3

Department of Orthopaedic Surgery, CHU Nantes

Nantes, France

4

Department of Orthopaedic Surgery Toulouse University Hospital

Toulouse, France